Relmada Therapeutics Q1 2024 GAAP EPS $(0.72) Beats $(0.84) Estimate
Relmada Therapeutics Q1 2024 GAAP EPS $(0.72) Beats $(0.84) Estimate
Relmada Therapeutics 2024年第一季度GAAP每股收益美元（0.72）超过预期（0.84）
Relmada Therapeutics (NASDAQ:RLMD) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of $(0.84) by 14.29 percent. This is a 17.24 percent increase over losses of $(0.87) per share from the same period last year.
Relmada Therapeutics（纳斯达克股票代码：RLMD）公布的季度亏损为每股0.72美元，比分析师共识估计的美元（0.84美元）高出14.29％。这比去年同期每股亏损0.87美元（0.87美元）增长了17.24％。